Defined and tunable peptide-lipid membrane interactions that trigger the release of liposome encapsulated drugs may offer a route to improve the efficiency and specificity of liposome-based drug delivery systems, but this require means to tailor the performance of the membrane active peptides. In this paper, the membrane activity of a de novo designed coiled coil peptide has been optimized with respect to sequence and size to improve release efficiency of liposome encapsulated cargo. The peptides were only membrane active when covalently conjugated to the liposomes. Two amino acid substitutions were made to enhance the amphipathic characteristics of the peptide, which increased the release by a factor of five at 1 µM. Moreover, the effect of peptide 2 length was investigated by varying the number of heptad repeats from 2 to 5, yielding the peptides KVC2-KVC5. The shortest peptide (KVC2) showed the least interaction with the membrane and proved less efficient than the longer peptides in releasing the liposomal cargo. The peptide with three heptads (KVC3) caused liposome aggregation whereas KVC4 proved to effectively release the liposomal cargo without causing aggregation. The longest peptide (KVC5) demonstrated the most defined a-helical secondary structure and the highest liposome surface concentration but showed slower release kinetics than KVC4. The four heptad peptide KVC4 consequently displayed optimal properties for triggering the release and is an interesting candidate for further development of bioresponsive and tunable liposomal drug delivery systems.
INTRODUCTION
A vast number of different natural and synthetic membrane active peptides have been described that can affect lipid membrane integrity. These membrane active peptides are often short (< 40 amino acids), amphipathic and cationic. 1 Many natural peptides demonstrate high affinities for lipid membranes, and further improvements in affinity can be made by conjugating various hydrophobic moieties to the peptides. [2] [3] [4] The interaction of membrane active peptides with a lipid membrane typically results in membrane partitioning and pore formation or disruption of the lipid bilayer and formation of mixed peptide-lipid micelles, as well as conformational changes in the peptide. 5 Small changes in the primary structure can result in a large difference in the peptide-lipid interaction. 6 Liposome-based drug delivery systems can improve the pharmacokinetics and biodistribution as well as reducing toxicity of pharmaceuticals. 7 About twelve liposome-based drugs have been 3 approved for clinical use while many more are in various stage of clinical trials. 8 The release of liposome-encapsulated drugs is vital for the drug molecule to become bioavailable and provide a therapeutic effect. This process is typically slow and relies on passive diffusion as well as liposomal degradation. Thus, it is of great interest to develop strategies for tunable and triggered drug release from liposomes in order to reliably achieve drug concentrations within the therapeutic window. 9 Due to the lipid membrane disruptive mechanisms of membrane active peptides, they can potentially be utilized to modulate the release of liposome encapsulated drugs. Al-Ahmady et al.
showed that lipid-bilayer-embedded leucin-zippers could improve the release of a model drug from temperature responsive liposomes by exploiting the unfolding of the peptides caused by mild hyperthermia. 10 Additionally, the primary structure of peptides conjugated to liposomes can be tailored to include recognition sites for enzymes typically overexpressed in the tumor microenvironment, such as matrix metalloproteinase 9 (MMP-9). Mallik and co-workers exploited MMP-9 responsive membrane active peptides to trigger the release of encapsulated species as a result of the proteolytic cleavage of the peptides. 11, 12 Membrane active peptides can thus be used as active and bioresponsive components in liposome-based drug delivery systems, and they should ideally be bound to the liposomes to ensure co-transportation and effective co-localization of peptides and liposomes. Conjugation of membrane active peptides to liposomes may, however, effect their membrane activity and means to optimize, modulate and trigger their effect on the drug release rate are thus central.
We have recently demonstrated that a de novo designed 29 residue coiled coil peptide (KVC) 13 was highly membrane active when covalently conjugated to a lipid membrane. 14 The peptide-lipid conjugation was accomplished through a Michael addition reaction between the N-terminal Cys 4 residue in the peptide and maleimide-functionalized lipids (MPB-PE) mixed into POPC liposomes.
The peptide-lipid conjugation resulted in a rapid peptide and maleimide concentration dependent permeabilization of the liposomes. In the absence of MPB-PE, or when excluding the Cys, no interactions between the peptides and the liposomes could be observed. The membrane partitioning was significantly reduced in the presence of complementary peptides (EI and EV) which were designed to heterodimerize with KVC and fold into coiled coils. This competitive interaction reduced the possibilities for KVC to interact with the lipid membrane. However, when introducing a third peptide (KI) that could outcompete KVC in the heterodimer, the membrane permeabilizing effect was reestablished. The possibility to dynamically tune, inhibit and activate release of compounds from liposomes are highly interesting in the development of more sophisticated liposome-based drug delivery systems. In addition, possibilities to introduce both specificity and triggered response are design features of high relevance in the development of many other therapeutic applications of membrane active peptides, including antimicrobial peptides.
Here we have investigated the effect of peptide length and sequence to further optimize KVC for potential drug delivery applications and to shed light on the mechanisms involved in the membrane partitioning processes. KVC was originally designed as a four heptad repeat coiled coil 13 with an additional N-terminal Cys included to facilitate conjugation to lipids 14 or polymers. 15 Each heptad is a seven-amino acid repeat of hydrophobic (h) and polar (p) residues in a hpphppp pattern, which is often seen in coiled coils. The repeat is commonly denoted as (abcdefg)n where n is the number of repeats and a-g show the relative positions of the amino acids in a helical wheel diagram. In KVC, the hydrophobic residues (Leu and Val) are in positions a and d and a number of charged
Lys in e and g gives the peptide a positive net charge (+5) at neutral pH. An asparagine (Asn) residue was incorporated in position a in the third heptad to promote formation of heterodimeric structures with aligned and parallel orientation upon interaction with complementary peptides (EI and EV). In addition, a tryptophan (Trp) was incorporated in position f in the third heptad as a chromophore. However, having a polar residue in the hydrophobic face and a highly hydrophobic residue in the hydrophilic face likely influences the membrane activity of the peptide. A new peptide, KVC4, was thus synthesized where the Asn and Trp residues were replaced with a hydrophobic (Val) and a charged residue (Glu), respectively. Each substitution was done to match the residues found on the respective positions elsewhere in the peptide sequence, thus generating a peptide with four identical heptad repeats. As expected, this peptide showed improved membrane activity compared to KVC. Moreover, the effect of the size of the peptide on the membrane activity was investigated by altering the number of identical heptad repeats from two to five, thus eliminating the influence of single non-repeating residues. The resulting peptides, KVC2, KVC3, KVC4, and KVC5, were membrane active, but only when covalently conjugated to the liposomes.
The peptides showed distinctly different kinetics in the release of liposome encapsulated 5(6)-carboxyfluorescein (CF), and KVC3-KVC5 outperformed KVC with respect to CF release efficiency, requiring lower peptide concentrations and shorter times to trigger the release. In contrast to KVC, KVC3-KVC5 adopted a-helical secondary structure when conjugated to the liposomes, which indicate improved partition-folding coupling.
This work further indicates that the KVC-based peptides are highly interesting for design of liposome-based drug delivery systems with triggered and tunable release and highlights the importance of optimizing sequence and size to obtain peptides with desired abilities to modulate lipid membrane integrity. MPB-PE has a terminal maleimide moiety that can react with the thiol group in the Cys containing peptides through a Michael addition reaction, anchoring the peptides to the liposome surface ( Figure 2A ). In the absence of MPB-PE (0 mol% MPB-PE liposomes) the CF release caused by addition of KVC and KVC4 was < 3 % and < 1 %, respectively ( Figure 2B ). This level of CF release was similar to the spontaneous leakage of CF (< 2 %, Figure S1 ) and consistent with previous studies of KVC and related peptides. 14 In contrast, rapid and peptide concentration dependent release was observed from 5 mol% MPB-PE liposomes upon addition of the peptides.
As expected KVC4 proved more efficient than KVC in releasing encapsulated CF ( Figure 2B ). The CF release was triggered at significantly lower peptide concentrations for KVC4 and the amount of CF release was about a factor of five higher than for KVC at a concentration of 1 µM.
Interestingly, the thermodynamic profiles obtained by isothermal titration calorimetry (ITC)
indicated that the interaction of KVC4 with the liposomes was slightly less exothermic than for KVC ( Figure interaction the peptide-lipid interactions were endothermic, which was further confirmed by the lack of interactions between KVC or KVC4 and 0 mol% MPB-PE liposomes ( Figure 2E and Figure   S2 ). Conjugation was thus a prerequisite in order for the peptides to interact with the lipid membrane and likely facilitated an entropy driven membrane partitioning process. The difference in net charge between KVC (+5 at pH 7.4) and KVC4 (+4 at pH 7.4) due to the replacement of Trp for Glu in KVC4 may contribute to the difference in the calorimetric heat traces between the two peptides but differences in membrane partitioning and peptide oligomerization and folding are also contributing factors considering the large differences in CF release for the two peptides. None of the peptides induced any increase in CF release when exposed to liposomes with 0 mol% MPB-PE liposomes ( Figure 3B ). However, all peptides triggered increased membrane permeability and CF release from 5 mol% MPB-PE liposomes albeit to a different extent and with different kinetics ( Figure 3C ). The extent of the release was substantially lower for KVC2 than for KVC3-KVC5, which all showed fairly similar amount of CF being released at the highest peptide concentrations (5-10 µM) after 120 min incubation. On the other hand, large differences in the release kinetics were observed for the different peptides. The fastest CF release was obtained for KVC4, followed by KVC5, KVC3, and KVC2, The interaction and partitioning of similar membrane active peptides with lipid membranes often result in conformational changes due to the amphipathic character of the folded peptides. 21 However, despite being found to partition into the membrane and trigger CF release when conjugated to liposomes, KVC was not found to fold. 14 Circular dichroism (CD) spectroscopy of KVC2-KVC5 indicated that all peptides except KVC5 existed as random coils in solution ( Figure   5A -D). The free KVC5 in PB showed some tendencies to adopt an a-helical conformation, likely due to homodimerization which tends to be more prominent the longer the peptide. 22 In contrast to KVC, changes in secondary structure were seen for all the KVC2-KVC5 peptides when conjugated to 5 mol% MPB-PE liposomes. The longer the peptide, the larger the change in secondary structure and the more pronounced the increase in helicity ( Figure 5E-H) . In comparison, when incubating the peptides with 0 mol% MPB-PE liposomes no such changes were observed ( Figure 5I-L) . The secondary structures of the peptides incubated with 0 mol% MPB-PE and KVC4, respectively, over a period of 24 hours. Since the CF release occurred on a time scale of less than 60 minutes for both KVC3 and KVC4 under these conditions, this indicates that the peptides may contribute to the permeabilization of the membrane even though not fully folded.
This was also the case for KVC as previously demonstrated. 14 However, one must keep in mind that the CD spectra are linear combinations of the secondary structures for all the peptides in the sample, including those in the solution and peptides that had been conjugated to, but not yet partitioned into, the lipid bilayer. The CD data, however, clearly indicates that a large fraction of the KVC3-KVC5 peptides are folded when conjugated and the more efficient CF release seen for these peptides compared to KVC can thus likely be attributed to a more efficient partition-folding coupling. Surface plasmon resonance (SPR) was utilized to investigate both the surface concentration of peptides conjugated to the liposomes and their accessibility to interactions with the complementary peptide EI ( Figure 6A ). Liposomes with 5 mol% MPB-PE were immobilized on a Biacore L1 chip and subsequently exposed to injections of KVC2-KVC5 followed by injections of EI. The SPR response after injection of KVC2-KVC5 increased as a function of peptide length, both as a result of increasing molecular weight of the peptides and the amount of any peptide bound to the liposomes. KVC2 gave the lowest response and KVC5 the highest ( Figure 6B ). By normalizing the responses with respect to both the molecular weight of the peptides and the immobilization level of the liposomes the number of peptides per lipid could be calculated ( Figure 6C ). Interestingly, whereas both KVC2 and KVC3 were found to bind to the liposomes at a level corresponding to the maximum surface concentration of MPB-PE, also considering the possibility of translational movement of lipids from the inner to the outer lipid leaflet, the surface concentration of both KVC4
and KVC5 exceeded that of MPB-PE. A similar effect was previously seen for a related de novo designed peptide, JR2KC, and indicates that peptides can bind non-covalently to the lipid membranes once the membrane permeabilization process has been initiated. 23 To further study the accessibility of the membrane bound peptides for competing interactions, the complementary peptide EI was introduced to KVC2-KVC5-functionalized liposomes. EI is designed to heterodimerize with KVC and fold into a coiled coil, 13 and was also found to fold in the presence of KVC4 and KVC5 ( Figure S3 ). EI is Glu rich with a net charge of -5 at neutral pH and has previously been shown not to interact with liposomes. 14 EI did, however, bind extensively to liposomes with conjugated KVC2 (Figure 6D ), likely as a result of electrostatic interactions considering the opposite charge of the two peptides (+2 for KVC2 and -5 for EI). The ratio of EI to KVC2 was about 1:1, which indicates that KVC2 did not partition into the membrane to any larger extent, in agreement with the CD and CF release data. Conjugated KVC3 and KVC4 were both interacting with EI but to a lesser extent than KVC2, which indicates that their hydropic and charged residues are less available for interactions due to membrane partitioning. It is not possible to determine whether only about 50% of the peptides were embedded in the membrane or if the process was reversible and that the injection of EI caused the peptides to associate with EI instead
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of interacting with the lipid membrane. A coiled coil peptide with a similar sequence as KVC3, (KIAALKE)3, designed by Alexander Kros et al, 3 was also shown to interact with the lipid membrane and adopt a distinct a-helical secondary structure when tethered to the lipid membrane by means of peptide-lipidation. In addition, when introducing liposomes functionalized with a complementary peptide, (EIAALEK)3, peptide heterodimerization occurred, resulting in liposome fusion, indicating that the interaction of the (KIAALKE)3 peptide with the lipid membrane was reversible. However, for the KVC2-KVC5 peptides, when increasing peptide length, the peptidelipid interactions became more pronounced. Hence, no association of KVC5 and EI could be observed, further indicating that this peptide was fully and irreversibly partitioned in the membrane under these conditions. 
CONCLUSIONS
In summary, a systematic approach to optimize the membrane activity of the coiled coil peptide KVC was investigated. As a first step, the amphipathic characteristics of KVC were improved by replacing Asn in position 17 by Val and Trp in position 22 by Glu, rendering the peptide KVC4.
KVC4 was found to trigger release of liposome encapsulated CF faster and more efficiently than KVC when conjugated via an N-terminal Cys to POPC liposomes containing the maleimide lipid MPB-PE. In the absence of MPB-PE no CF release or peptide-lipid interactions occurred for neither of the peptides. ITC confirmed that the peptide-lipid membrane interactions were exothermic but occurred only because of the Cys-maleimide conjugation. To further investigate the mechanisms involved and the dependence on peptide length of the membrane activity, the number of heptad repeats was varied from two to five. Irrespectively of length, conjugation led to release of encapsulated CF. The CF release triggered by KVC3-KVC5 was more rapid than for KVC and KVC2, and required lower concentrations. The most rapid release was obtained for KVC4. In contrast to KVC and KVC2, KVC3-KVC5 adopted a defined a-helical conformation when conjugated, further supporting a more definite partition-folding coupling. The CF release efficiency could not solely be predicted by analyzing folding of peptides conjugated to liposomes, since the competitive interaction of peptide homodimerization also contributed to the folding.
Thus, there were no clear evidence that folding of the peptides was a prerequisite for the increase in membrane permeability, though it proved highly likely that the conjugated amphipathic peptide probably folded upon interaction with the lipid bilayer. Interestingly, conjugation of KVC3 resulted in liposome aggregation whereas for the other peptides only minor changes in liposome size were observed upon conjugation. The conjugated peptide to MPB-PE ratio increased from about 1:1 for KVC2-KVC4 to about 2:1 for KVC5. The high liposome surface concentration obtained for KVC5
was likely an effect of both conjugation of peptide oligomers and recruitment of non-conjugated peptides to sites where the lipid bilayer integrity was disrupted. In addition, whereas KVC2, and to a certain extent also KVC3 and KVC4, could interact with a complementary peptide after conjugation, KVC5 did not which indicates that it was efficiently and irreversibly buried in the lipid bilayer or already folded into oligomers. A comparison of the properties of KVC2-KVC5 and the parameters investigated in this paper are summarized in Table 1 , and clearly show the nontrivial effects of varying peptide length on peptide-lipid membrane interactions. Difficulties to rationally predict the performance of designed membrane active peptides highlight the need of systematic studies to optimize peptide sequences and function. For further work on triggered release, KVC4 is an attractive candidate since it induced rapid membrane permeabilization and efficient CF release without causing liposome aggregation. The highly defined intermolecular interactions involved in oligomerization and folding of the coiled coils used here will also facilitate further development of strategies for bioresponsive and tunable liposome content release, which is requirement for practical implementation in drug delivery systems. 
MATERIALS AND METHODS

General.
The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dioleoylsn-glycero-3-phophoethanolamine-N-(4-(p-maleimidophenyl)butyramide) (MPB-PE) were purchased from Avanti Polar Lipids (Alabaster, USA). Sensor chip L1 was purchased from GE Healthcare (Uppsala, Sweden). All other chemicals were purchased from Sigma Aldrich (Saint Louis, USA).
Peptide synthesis were performed on a Quartet automated peptide synthesizer (Gyros protein technologies) using standard fluroenylmethoxycarbonyl (Fmoc) chemistry. The sequences of KVC, KVC2-KVC5 are shown in Figure 1A and 3A. The sequence of EI was EIAALEKEIAALEKENAALEWEIAALEK. KVC and EI were synthesized as described previously. 13 The peptides KVC2-KVC5 were synthesized on a 50 µM scale using a Rink-amide 
